206 related articles for article (PubMed ID: 37896184)
1. Dual-Targeted Therapy in HER2-Overexpressing Breast Cancer with Trastuzumab and Novel Cholesterol-Based Nioplexes Silencing Mcl-1.
Pengnam S; Opanasopit P; Rojanarata T; Yingyongnarongkul BE; Thongbamrer C; Plianwong S
Pharmaceutics; 2023 Oct; 15(10):. PubMed ID: 37896184
[TBL] [Abstract][Full Text] [Related]
2.
Balgobind A; Daniels A; Ariatti M; Singh M
Pharmaceutics; 2023 Apr; 15(4):. PubMed ID: 37111675
[TBL] [Abstract][Full Text] [Related]
3. Synergistic Effect of Doxorubicin and siRNA-Mediated Silencing of Mcl-1 Using Cationic Niosomes against 3D MCF-7 Spheroids.
Pengnam S; Plianwong S; Patrojanasophon P; Radchatawedchakoon W; Yingyongnarongkul BE; Opanasopit P; Charoensuksai P
Pharmaceutics; 2021 Apr; 13(4):. PubMed ID: 33919902
[TBL] [Abstract][Full Text] [Related]
4. Magnetic nanocarriers for the specific delivery of siRNA: Contribution of breast cancer cells active targeting for down-regulation efficiency.
Bruniaux J; Allard-Vannier E; Aubrey N; Lakhrif Z; Ben Djemaa S; Eljack S; Marchais H; Hervé-Aubert K; Chourpa I; David S
Int J Pharm; 2019 Oct; 569():118572. PubMed ID: 31352052
[TBL] [Abstract][Full Text] [Related]
5. ScFv-decorated PEG-PLA-based nanoparticles for enhanced siRNA delivery to Her2⁺ breast cancer.
Dou S; Yang XZ; Xiong MH; Sun CY; Yao YD; Zhu YH; Wang J
Adv Healthc Mater; 2014 Nov; 3(11):1792-803. PubMed ID: 24947820
[TBL] [Abstract][Full Text] [Related]
6. Functionalized immunostimulating complexes with protein A via lipid vinyl sulfones to deliver cancer drugs to trastuzumab-resistant HER2-overexpressing breast cancer cells.
Rodríguez-Serrano F; Mut-Salud N; Cruz-Bustos T; Gomez-Samblas M; Carrasco E; Garrido JM; López-Jaramillo FJ; Santoyo-Gonzalez F; Osuna A
Int J Nanomedicine; 2016; 11():4777-4785. PubMed ID: 27698563
[TBL] [Abstract][Full Text] [Related]
7. The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity.
Dragowska WH; Weppler SA; Qadir MA; Wong LY; Franssen Y; Baker JH; Kapanen AI; Kierkels GJ; Masin D; Minchinton AI; Gelmon KA; Bally MB
BMC Cancer; 2011 Oct; 11():420. PubMed ID: 21961653
[TBL] [Abstract][Full Text] [Related]
8. c-Myc dependent expression of pro-apoptotic Bim renders HER2-overexpressing breast cancer cells dependent on anti-apoptotic Mcl-1.
Campone M; Noël B; Couriaud C; Grau M; Guillemin Y; Gautier F; Gouraud W; Charbonnel C; Campion L; Jézéquel P; Braun F; Barré B; Coqueret O; Barillé-Nion S; Juin P
Mol Cancer; 2011 Sep; 10():110. PubMed ID: 21899728
[TBL] [Abstract][Full Text] [Related]
9. Multifunctional peptide-lipid nanocomplexes for efficient targeted delivery of DNA and siRNA into breast cancer cells.
Wan Y; Dai W; Nevagi RJ; Toth I; Moyle PM
Acta Biomater; 2017 Sep; 59():257-268. PubMed ID: 28655658
[TBL] [Abstract][Full Text] [Related]
10. Dual-targeted therapy in HER2-positive breast cancer cells with the combination of carbon dots/HER3 siRNA and trastuzumab.
Shu M; Gao F; Yu C; Zeng M; He G; Wu Y; Su Y; Hu N; Zhou Z; Yang Z; Xu L
Nanotechnology; 2020 Aug; 31(33):335102. PubMed ID: 32303014
[TBL] [Abstract][Full Text] [Related]
11. Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.
Takeda T; Yamamoto H; Kanzaki H; Suzawa K; Yoshioka T; Tomida S; Cui X; Murali R; Namba K; Sato H; Torigoe H; Watanabe M; Shien K; Soh J; Asano H; Tsukuda K; Kitamura Y; Miyoshi S; Sendo T; Toyooka S
PLoS One; 2017; 12(2):e0171356. PubMed ID: 28158234
[TBL] [Abstract][Full Text] [Related]
12. Polymeric delivery of siRNA for dual silencing of Mcl-1 and P-glycoprotein and apoptosis induction in drug-resistant breast cancer cells.
Aliabadi HM; Mahdipoor P; Uludağ H
Cancer Gene Ther; 2013 Mar; 20(3):169-77. PubMed ID: 23449477
[TBL] [Abstract][Full Text] [Related]
13. Combination of Nanovectorized siRNA Directed against Survivin with Doxorubicin for Efficient Anti-Cancer Activity in HER2+ Breast Cancer Cells.
Eljack S; Allard-Vannier E; Misericordia Y; Hervé-Aubert K; Aubrey N; Chourpa I; Faggad A; David S
Pharmaceutics; 2022 Nov; 14(11):. PubMed ID: 36432729
[TBL] [Abstract][Full Text] [Related]
14. Lack of acquired resistance in HER2-positive breast cancer cells after long-term HER2 siRNA nanoparticle treatment.
Gu S; Ngamcherdtrakul W; Reda M; Hu Z; Gray JW; Yantasee W
PLoS One; 2018; 13(6):e0198141. PubMed ID: 29879129
[TBL] [Abstract][Full Text] [Related]
15. Overcoming Akt Induced Therapeutic Resistance in Breast Cancer through siRNA and Thymoquinone Encapsulated Multilamellar Gold Niosomes.
Rajput S; Puvvada N; Kumar BN; Sarkar S; Konar S; Bharti R; Dey G; Mazumdar A; Pathak A; Fisher PB; Mandal M
Mol Pharm; 2015 Dec; 12(12):4214-25. PubMed ID: 26505213
[TBL] [Abstract][Full Text] [Related]
16. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Lupu R
Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
[TBL] [Abstract][Full Text] [Related]
17. MEK inhibition increases lapatinib sensitivity via modulation of FOXM1.
Gayle SS; Castellino RC; Buss MC; Nahta R
Curr Med Chem; 2013; 20(19):2486-99. PubMed ID: 23531216
[TBL] [Abstract][Full Text] [Related]
18. Targeted silencing of the MCL-1 gene using multi-layered dendrimer-based nanoconstructs achieves efficient tumor regression in xenografted mice models.
Tambe P; Salve R; Choudhary P; Kumar P; Jadhav S; Paknikar KM; Gajbhiye V
Int J Pharm; 2023 Mar; 634():122659. PubMed ID: 36720446
[TBL] [Abstract][Full Text] [Related]
19. Dual HER2 Targeting with Trastuzumab and Liposomal-Encapsulated Doxorubicin (MM-302) Demonstrates Synergistic Antitumor Activity in Breast and Gastric Cancer.
Espelin CW; Leonard SC; Geretti E; Wickham TJ; Hendriks BS
Cancer Res; 2016 Mar; 76(6):1517-27. PubMed ID: 26759238
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2.
McKeage K; Perry CM
Drugs; 2002; 62(1):209-43. PubMed ID: 11790161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
